Both were approved by the US Food and Drug Administration (FDA) on the basis of randomized phase 3 clinical trials that demonstrated an improvement in pain in patients with metastatic prostate cancer. The 2 radiopharmaceuticals, strontium-89 and samarium-153 EDTMP, are beta-particle emitters. None of these 4 agents has been proved to prolong overall survival (OS) in large phase 3 randomized trials. 6Ĭurrently, 4 bone-targeted therapies are available for men with prostate cancer, including zoledronic acid (Zometa), denosumab (Prolia), samarium-153 ethylene diamine tetramethylene phosphonate (EDTMP Quadramet), and strontium-89 (Metastron). More than 2.5 million American men are currently living with prostate cancer. Unmet Need in Patients with Prostate Cancer and Bone MetastasesĪccording to the National Cancer Institute, in 2013, more than 238,500 men will be diagnosed with prostate cancer and more than 29,700 will die from the disease. A retrospective, observational study using health insurance claims data for episodes of care from September 2002 to June 2011 demonstrated that, among patients with prostate cancer, the cost of a skeletal-related event ranged from approximately $11,700 for an outpatient episode to more than $54,000 for an inpatient episode. Patients with prostate cancer and bone metastases utilize an inordinate amount of healthcare resources. 4 The prostate cancer–related costs made up approximately 31% of the total costs, or more than $34,000 per patient. The model estimated total lifetime medical costs of approximately $110,500 per patient (in 2004 US dollars). These cost estimates were then combined with survival data to determine the total lifetime costs and the prostate cancer–related lifetime costs. The medical cost data were obtained from the SEER-Medicare database and were estimated during specific phases of cancer care. Using Surveillance, Epidemiology and End Results (SEER) data, Stokes and colleagues estimated the survival of men aged ≥65 years who were diagnosed with prostate cancer between the calendar years of 19. ![]() Prostate cancer places a significant burden on the US healthcare system. 2īone metastases have serious and debilitating clinical consequences, including pain that requires opioids and/or radiotherapy, hypercalcemia, pathologic fracture, spinal cord compression, and nerve root compression. 1 The median survival after the diagnosis of bone metastasis associated with prostate cancer is approximately 3 years. Among patients with metastatic prostate cancer, up to approximately 90% have bone metastases. Prostate cancer is the second leading cause of cancer-related death in the United States among men and the most frequently diagnosed cancer in American males.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |